Global
About
Development milestones Mission&Vision Founder Research Achievement
Technology Platforms
Single domain antibody Five core technology platforms
PIPELINE
BUSINESS PARTNERSHIPS
Product Out-Licensing Co-Development
INVESTORS
CAREERS
Our Story Social Recruitment
News
Company News Media
Contact Us
Company Address Online Message
×
Pipeline

Progress and introduction
of main products

Pipeline
Precision-focused product portfolio strategy，accelerated development of competitive advantage products.
Respiratory diseases
Project
Target
Indication
Route of Administration
Clinical trial area
Pre-Clinical
Discovery
CMC
Toxicology
IND
Clinical Phase I
Clinical Phase II
Rights
LQ036
IL-4Rα
Autoimmune
EOS Asthma
Inhaled
2023 :Australia Phase I SAD completed
Global
EOS Asthma
Inhaled
March 2025 :phase IIa PoC readout, IIb trial initiated in July 2025
Global
COPD
Inhaled
Q2 2026: China Phase II trail initiation
Global
LQ036
More
LQ043H
TSLP
Autoimmune
Asthma
Inhaled
Q1-2026: Phase Ib PoC trial initiation
Global
LQ043H
More
LQ059
Notch2
Autoimmune
Cystic fibrosis
Inhaled
CMC
Global
LQ059
More
Inflammatory diseases
Project
Target
Indication
Route of Administration
Clinical trial area
Pre-Clinical
Discovery
CMC
Toxicology
IND
Clinical Phase I
Clinical Phase II
Rights
LQ080
TL1A/IL-23p19
Autoimmune
IBD
SC
CMC
Global
LQ080
More
LQ083
TL1A
IBD
Oral
PCC
Global
LQ083
More
LQ091
Undisclosed
Autoimmune
Oral
Leads optimization
Global